Palliative chemotherapy for pancreatic malignancies

Surg Clin North Am. 2010 Apr;90(2):365-75. doi: 10.1016/j.suc.2009.12.005.

Abstract

Metastatic pancreatic cancer is often one of the most challenging malignancies a medical oncologist faces. Although the primary endpoint of many studies remains overall survival, palliation and quality of life are now more commonly being addressed. The author discusses the most common chemotherapeutic modalities for the treatment of metastatic pancreatic cancer, such as single agent chemotherapy, combination therapy, targeted therapy, and second line treatment.

Publication types

  • Review

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / mortality
  • Angiogenesis Inhibitors / administration & dosage
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Capecitabine
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Deoxycytidine / therapeutic use
  • ErbB Receptors / antagonists & inhibitors
  • Erlotinib Hydrochloride
  • Everolimus
  • Fluorouracil / analogs & derivatives
  • Fluorouracil / therapeutic use
  • Gemcitabine
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Irinotecan
  • Organoplatinum Compounds / administration & dosage
  • Oxaliplatin
  • Palliative Care*
  • Pancreatic Neoplasms / drug therapy*
  • Pancreatic Neoplasms / mortality
  • Quality of Life
  • Quinazolines / administration & dosage
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Immunosuppressive Agents
  • Organoplatinum Compounds
  • Quinazolines
  • Oxaliplatin
  • Deoxycytidine
  • Bevacizumab
  • Capecitabine
  • Irinotecan
  • Everolimus
  • Erlotinib Hydrochloride
  • ErbB Receptors
  • Fluorouracil
  • Sirolimus
  • Camptothecin
  • Gemcitabine